Utrecht spinout developing FOXO4-derived senolytic peptides to selectively destroy senescent cells in cancer and chronic disease.
Seattle biotech using a non-viral lipid delivery platform to deliver gene-directed payloads that destroy senescent cells.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →